ISIN | LU2050612402 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
Peculiarities |
Current Price * | 79.64 USD | 15.04.2025 |
---|---|---|
Previous Price * | 77.82 USD | 14.04.2025 |
52 Week High * | 108.58 USD | 26.07.2024 |
52 Week Low * | 72.17 USD | 09.04.2025 |
NAV * | 79.64 USD | 15.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 367,024,352 | |
Unit/Share Assets *** | 105,063,796 | |
Trading Information SIX |
YTD Performance | -11.68% |
31.12.2024 - 15.04.2025
31.12.2024 15.04.2025 |
---|---|---|
YTD Performance (in CHF) | -20.15% |
31.12.2024 - 15.04.2025
31.12.2024 15.04.2025 |
1 month | -12.23% |
17.03.2025 - 15.04.2025
17.03.2025 15.04.2025 |
3 months | -10.17% |
15.01.2025 - 15.04.2025
15.01.2025 15.04.2025 |
6 months | -20.96% |
15.10.2024 - 15.04.2025
15.10.2024 15.04.2025 |
1 year | -19.09% |
15.04.2024 - 15.04.2025
15.04.2024 15.04.2025 |
2 years | -24.81% |
17.04.2023 - 15.04.2025
17.04.2023 15.04.2025 |
3 years | -31.33% |
19.04.2022 - 15.04.2025
19.04.2022 15.04.2025 |
5 years | -28.57% |
15.04.2020 - 15.04.2025
15.04.2020 15.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Bristol-Myers Squibb Co | 3.60% | |
---|---|---|
Gilead Sciences Inc | 3.55% | |
Amgen Inc | 3.53% | |
Novartis AG Registered Shares | 3.52% | |
Alnylam Pharmaceuticals Inc | 3.40% | |
Vertex Pharmaceuticals Inc | 3.33% | |
Krystal Biotech Inc | 3.32% | |
Lonza Group Ltd | 3.32% | |
Takeda Pharmaceutical Co Ltd | 3.20% | |
PTC Therapeutics Inc | 3.14% | |
Last data update | 31.03.2025 |
TER *** | 0.94% |
---|---|
TER date *** | 31.12.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.72% |
Ongoing Charges *** | 0.95% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |